HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowin, J. Articles by Christadoss, P. Search for Related Content PubMed PubMed Citation Articles by Rowin, J. Articles by Christadoss, P. Related Collections Myasthenia All Clinical trials Clinical trials Observational study (Cohort, Case control)

Etanercept treatment in corticosteroid-dependent myasthenia gravis

From the Section of Neuromuscular Disease (Drs. Rowin and Meriggioli), Department of Neurology and Rehabilitation, University of Illinois at Chicago, and Department of Neurological Sciences (Dr. Leurgans), Rush University Medical Center, Chicago, IL, and Department of Microbiology and Immunology (Drs. Tüzün and Christadoss), University of Texas at Galveston.

Address correspondence and reprint requests to Dr. M.N. Meriggioli, Section of Neuromuscular Disease, Department of Neurology and Rehabilitation, University of Illinois at Chicago, 912 S. Wood St., 855N NPI, M/C 796, Chicago, IL 60612-7330; e-mail: mmerig{at}uic.edu

The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.

Received May 11, 2004. Accepted in final form August 2, 2004.

This article has been cited by other articles:

				D Hilton-Jones When the patient fails to respond to treatment: myasthenia gravis Practical Neurology, November 1, 2007; 7(6): 405 - 411. [Abstract] [Full Text] [PDF]

				H. Yang, E. Tuzun, D. Alagappan, X. Yu, B. G. Scott, A. Ischenko, and P. Christadoss IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1 J. Immunol., August 1, 2005; 175(3): 2018 - 2025. [Abstract] [Full Text] [PDF]